Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced back with top-line results from its phase II study in obesity. Results showed robust reductions in body mass index and serum lipids, along with improvements in blood pressure with no imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate. The data showed liver-fat loss similar to Novo Nordisk A/S’ GLP-1 drug Wegovy (semaglutide). Read More
Cellcentric's inobrodib, a novel drug with a distinct mechanism of action, shows promise in treating various hematological malignancies, as revealed in a recent publication in Cancer Cell. Read More
Arriving on the gene therapy scene with an undisclosed seed funding sum, Alveogene is tackling respiratory diseases with high unmet need via a next-generation lentiviral delivery platform to advance into the clinic a candidate for rare inherited disorder alpha-1 antitrypsin deficiency. Read More
Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value. Read More
Artificial Intelligence (AI) driven tools have the ability to design new drugs, with a bit of help from humans, said Anders Hogner, from Astrazeneca plc’s R&D department at the Bio-IT World Conference & Expo Europe in London. “We don’t have anything out there yet,” he added, but the company appears to be working on it. Read More
You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Read More
New hires and promotions in the biopharma industry, including: AC Immune, Akari, Annovis, Aptose, Aqilion, Cyclerion, Johnson and Johnson, Silence. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acadia, Astellas, Benitec, Briacell, Calliditas, Chromadex, Clarity, Cybin, Galderma, Gilgamesh, Inipharm, Jasper, Lexicon, Neurogene, Partner, Polaris, Protara, Scineuro and Sol-Gel. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aexon, Cerecin, CNX, Ligand, Maat, Navidea, NLS, Palvella, Pharmnovo, Sanofi. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Edgewise, Everest, Mithra, Orchard, Scilex, Soligenix. Read More
